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Abstract
Background
Trypanosoma (T.) evansi is a dyskinetoplastic variant of T. brucei that has gained the ability
to be transmitted by all sorts of biting flies. T. evansi can be divided into type A, which is the
most abundant and found in Africa, Asia and Latin America and type B, which has so far
been isolated only from Kenyan dromedary camels. This study aimed at the isolation and
the genetic and phenotypic characterisation of type A and B T. evansi stocks from camels in
Northern Ethiopia.
Methodology/principal findings
T. evansiwas isolated in mice by inoculation with the cryopreserved buffy coat of parasito-
logically confirmed animals. Fourteen stocks were thus isolated and subject to genotyping
with PCRs targeting type-specific variant surface glycoprotein genes, mitochondrial minicir-
cles and maxicircles, minisatellite markers and the F1-ATP synthase γ subunit gene. Nine
stocks corresponded to type A, two stocks were type B and three stocks represented mixed
infections between A and B, but not hybrids. One T. evansi type A stock was completely aki-
netoplastic. Five stocks were adapted to in vitro culture and subjected to a drug sensitivity
assay with melarsomine dihydrochloride, diminazene diaceturate, isometamidium chloride
and suramin. In vitro adaptation induced some loss of kinetoplasts within 60 days. No corre-
lation between drug sensitivity and absence of the kinetoplast was observed. Sequencing
the full coding sequence of the F1-ATP synthase γ subunit revealed new type-specific sin-
gle nucleotide polymorphisms and deletions.
Conclusions/significance
This study addresses some limitations of current molecular markers for T. evansi genotyp-
ing. Polymorphism within the F1-ATP synthase γ subunit gene may provide new markers to
identify the T. evansi type that do not rely on variant surface glycoprotein genes or kineto-
plast DNA.
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Author Summary
Trypanosoma (T.) evansi causes surra in various animal species in Africa, Latin America
and Asia. Despite inducing important animal suffering, economic losses and being a
World Animal Health Organisation (OIE) notifiable disease, surra is severely neglected in
terms of awareness, control interventions and research into improved control tools. Most
serological tests can only detect T. evansi type A, while molecular tests rely on detection of
highly variable genes or on fragile kinetoplast DNA. Even more, the obscure T. evansi type
B, first isolated decades ago in Kenya, totally escapes surveillance due to absence of reliable
diagnostic tools. In the present study we isolated new type B stocks from Ethiopia, thus
suggesting that this type of T. evansi is probably more widely distributed than previously
thought. We further report on an alternative molecular marker for both types of T. evansi
and present data on the drug sensitivity of the Ethiopian isolates.
Introduction
Surra, a wasting disease caused by Trypanosoma (T.) evansi, is one of the non tsetse-transmit-
ted Animal African Trypanosomoses (AAT) occurring in Ethiopia. The disease imposes signif-
icant financial losses due to reduced fertility and mortality and is prohibiting the import of
highly productive yet trypanosusceptible cattle breeds [1–3]. T. evansi belongs to the subgenus
Trypanozoon, that also comprises T. brucei and T. equiperdum [4–6]. In terms of geographical
distribution, Trypanosoma equiperdum and T. evansi, causing respectively dourine in horses
and surra in livestock in Africa, Asia, and South America, have been far more successful than
T. brucei, a parasite confined to sub-Saharan Africa where its vector, the tsetse fly, is present
[7]. Recent phylogenetic studies suggest that T. evansi and T. equiperdum evolved from T. bru-
cei on several occasions and from genetically distinct T. brucei strains and therefore could be
considered as subspecies of T. brucei [8,9].
Trypanosomes are characterised by the presence of a structure called kinetoplast that corre-
sponds with the DNA (kDNA) of their unique mitochondrion. T. brucei kDNA contains 20–50
copies of maxicircles (about 23 kb) and a highly diverse set of thousands of minicircles (about
1 kb). Maxicircles contain rRNA coding regions and genes coding for subunits of the respira-
tory chain complexes while minicircles code for guide RNAs required for editing [10].
T. equiperdum and T. evansi are dyskinetoplastic (kDNA-) since they lack part of the kDNA
[8–11]. T. equiperdum typically has retained maxicircles, in some cases with substantial dele-
tions, but has lost its minicircle diversity. T. evansi does not have maxicircles and either shows
minicircle homogeneity or are akinetoplastic (kDNA) [10,12–14]. Based on their minicircle
restriction digestion profile, T. evansi can be divided into type A and type B [15,16].
T. evansi type A is the most abundant and is found in Africa, South America and Asia. It is
characterised by the presence of the gene for the variant surface glycoprotein (VSG) RoTat 1.2.
This RoTat 1.2 VSG is expressed early during infections resulting in the detectability of anti-
RoTat 1.2 antibodies in animals infected with T. evansi type A [17,18]. In contrast, T. evansi
type B is far less common and has so far been isolated only from camels in Kenya [16,19].
More recently, serological and molecular evidence for the presence of T. evansi type B in
Sudan, Ethiopia and Chad was published [20–24]. T. evansi type B lacks the RoTat 1.2 gene
and as a consequence, infections with this type are not detected with serological and molecular
tests based on RoTat 1.2 VSG, such as the CATT/T. evansi and RoTat 1.2 PCR [15,18,19,25].
So far, three molecular tests have been developed for the identification of T. evansi type B: the
EVAB PCR, targeting a type B-specific minicircle DNA sequence, and a PCR and a LAMP
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targeting a type B-specific VSG JN 2118Hu [15,19,26]. T. equiperdum is the least known para-
site of the Trypanozoon group, with very few isolates available for research, albeit new stocks
were isolated from Ethiopian and Venezuelan horses recently [24,27].
Unlike T. brucei, T. evansi and T. equiperdum cannot develop in tsetse flies due to their
inability to transform into the procyclic life stage. They can only survive in a mammalian host
where they produce ATP exclusively through glycolysis. In contrast to bloodstream forms,
ATP production in procyclic trypanosomes relies on oxidative phosphorylation and, therefore,
on the capacity to express the full set of corresponding mitochondrial genes, including some
which are encoded by the kDNA [10,28]. Bloodstream forms of T. evansi, T. equiperdum and
laboratory-generated T. brucei strains that have lost all or critical parts of their kDNA, can sur-
vive without kDNA due to specific single amino acid mutations in the gamma (γ) subunit of
the mitochondrial F1-ATP synthase [28]. Interestingly, the specific mutations/deletions in the
C-terminal region of F1-ATP synthase γ subunit enable differentiation among the Trypano-
zoon strains [8]. Furthermore, when the F1-ATP synthase γ subunits of T. evansi type A
(A281del), T. equiperdum (A273P) and the laboratory-generated T. brucei (L262P) strains are
overexpressed in a T. brucei γ subunit knock out strain, the latter can survive after loss of its
kinetoplast after treatment with DNA intercalating drugs such as acriflavin or ethidium bro-
mide [28,29]. Once the genetically modified T. brucei are independent from kDNAmainte-
nance and expression, they become multidrug resistant to the diamidine and phenanthridine
class of drugs [30].
In T. evansi, drug resistance has been reported in several type A strains originating from
Africa, Asia and Latin America [31–34]. Some Chinese strains appear to be innately resistant
to the phenanthridine class of drugs [35]. In contrast, nothing is known on the drug susceptibly
of the T. evansi type B strains. In a previous study, we reported that T. evansi infections are
very common in camels, equines, cattle and small ruminants in Tigray and Afar provinces in
Northern Ethiopia [20]. We also provided molecular and serological evidence that both T.
evansi type A and type B occur in these provinces. In that study, of those dromedary camels
that were parasitologically positive, buffy coat samples were collected and cryopreserved in liq-
uid nitrogen for later isolation of the parasite. We here report on the isolation, adaptation to in
vitro culture, genetic and phenotypic characterisation and in vitro drug sensitivity of T. evansi
type A and B from Northern Ethiopia.
Materials and Methods
Ethics statement
The Animal Experimentation Ethics Committee (AEEC) of the Institute of Tropical Medicine
(ITM) advised on the protocol for collection of blood samples from dromedary camels
(EXT2012-1) and for the isolation of trypanosomes via inoculation of mice (EXT2012-2) at the
College of Veterinary Medicine, Mekelle University. The study protocol for in vivo expansion
of trypanosomes at ITM was approved by the AEEC (BM2013-1). Collecting blood from cam-
els and experiments on mice were conducted according to the national guidelines of the Ethio-
pian Ministry of Livestock and Fishery Development and the Institutional Review Board of the
Ministry of Science and Technology.
In vivo isolation of parasites from cryopreserved buffy coat in mice
Details on the collection and cryopreservation of buffy coat samples from dromedary camels
that were parasitologically confirmed in the micro haematocrit centrifugation technique have
been fully described elsewhere [20]. Two hundred μl of thawed buffy coat were inoculated
intraperitoneally (IP) in two 25–30 g Swiss albino mice that were immunosuppressed with
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0.16 μg kg-1 body weight dexamethasone (Shanghai Central Pharmaceutical, China) one day
prior to inoculation [36]. Parasitaemia was checked in 5 μl of tail blood using the matching
method [37], starting from day 7 post-infection and subsequently on every third day. As soon
as trypanosomes were detected in at least one mouse, the animal was anaesthetised (the other
kept as a backup), its blood was collected on heparin by heart puncture, diluted in an equal vol-
ume of phosphate buffered saline glucose (PSG; 7.5 g/l Na2HPO42H2O, 0.34 g/l NaH2
PO4H2O, 2.12 g/l NaCl, 10 g/l D-glucose, pH 8) and subinoculated into four naïve mice (200 μl
each) which were monitored for parasitaemia as described above. Mice used as backup were
euthanised when the newly infected mice became positive. When parasitemia reached
about ± 107.8 cells ml−1 of blood, two of these parasitaemic mice were euthanised (the other
two were kept as back up) and blood was taken for subinoculation into four other naïve mice.
This protocol was repeated until the parasitaemia reached about 108.4 cells ml−1. At this stage
the stock was considered in vivo adapted. All four mice were anaesthetised and exsanguinated
by heart puncture in an equal volume of Triladyl-egg yolk-phosphate buffered saline glucose
(TEP) cryomedium [38] for cryopreservation in 1 ml aliquots.
In vivo expansion and purification of parasite populations
Cryostabilates were thawed in a water bath at 37°C and diluted in PSG to 1 trypanosome per
field (± 105.7 cells ml−1). Two-hundred μl volumes were injected IP in two naïve 20–30 g female
OF-1 mice (Charles River, Belgium). Starting from three days post infection (DPI), parasitae-
mia was monitored daily and harvested at first peak parasitemia, typically at day 4 to 5 post-
infection, as described above. Volumes of 0.5 ml of the blood were run over a mini Anion
Exchange Centrifugation Technique (mAECT) column to separate the trypanosomes from the
blood [39]. The trypanosomes eluted from the column were washed twice with 5 ml ice-cold
PSG by centrifugation at 1500 g for 15 min. After the last centrifugation, the supernatant PSG
was discarded and the trypanosome sediment was re-suspended in 100 μl of PSG. Part of this
suspension was used for in vitro culture adaptation. The remainder was centrifuged at 1500 g
for 5 min and the sediment was frozen at -80°C until DNA extraction. The isolates used for in
vivo isolation and expansion and the corresponding T. evansi type A and B specific PCR result
on their corresponding buffy coat DNA are indicated in Table 1.
In vitro adaptation in HMI-9 medium with horse serum
The highly concentrated trypanosome suspension in PSG was diluted to 2 x 105 cells ml−1 in
Hirumi’s modified Iscove’s medium 9 (HMI-9), complemented with 15% (v/v) heat-inacti-
vated foetal bovine serum (Gibco, Belgium) and 5% (v/v) heat-inactivated horse serum (Gibco,
Belgium) (abbreviated as HMI-9 (HS)) [40,41]. Parasites were seeded at 2 x 104, 2 x 103 and 2 x
102 cells ml−1, in a total volume of 500 μl in a 48-well plate (Nunc, Denmark) and incubated at
37°C and 5% CO2. After 72 hours, a well, where trypanosome density had increased above 2 x
105 cells ml−1, was used for further subpassage in 500 μl of HMI-9 (HS). The well with the high-
est density of viable parasites was then further maintained in HMI-9 without horse serum [40].
When possible, log phase growing in vitro cultures were scaled up in flasks (Nunc, Denmark)
to obtain larger numbers of parasites for cryostabilisation, DNA extraction and in vitro drug
sensitivity testing [42]. The in vitro growth curves of the different stocks were generated by
seeding cells at 1 x 104 cells ml−1 in 500 μl of HMI-9 in three replicate wells that were counted
every 24 h. The doubling times (Td) were calculated from the exponential part of the curve
using non-linear regression fitted with an exponential equation in GraphPad Prism 6 (Graph-
Pad, version 6, USA).
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Molecular characterisation of parasite populations
DNA extraction of trypanosome sediments prepared from the in vivo expanded and the in
vitro adapted populations was performed with DNA Isolation Kit (Roche Diagnostics, Ger-
many) following the protocol recommended for isolation of DNA from mammalian tissue.
From T.b. brucei AnTat 1.1E, T.b. gambiense LiTat 1.3, T.b. gambiense type II ABBA and T.
equiperdum Dodola 940, DNA was extracted using the Maxwell 16 Tissue DNA Purification
kit on a Maxwell 16 instrument according to the manufacturer's instructions (Promega, Bel-
gium). DNA concentrations were measured using the Nanodrop ND-1000 UV-Vis spectro-
photometer (NanoDrop Technologies, USA) and adjusted to 10 ng μl-1. A set of PCRs
targeting VSG genes (RoTat 1.2 and JN 2118Hu), maxicircle genes (ND4, ND5, ND7 and A6),
class A minicircles (miniA PCR) and class B minicircles (EVAB PCR) minisatellites (MORF-
2REP), P2 adenosine transporter (AT1) and the F1-ATP synthase γ subunit were adopted to
characterise the studied parasite populations [4,15,19,28,43–45]. Where applicable, the pub-
lished PCR protocols were adjusted to the requirements of the HotStarTaq Plus DNA polymer-
ase (Qiagen, Germany). Primer sequences, reaction mixture contents, cycling conditions and
expected amplicon size are described and referenced in Table 2. All PCR amplifications were
carried out in 200 μl thin-wall PCR tubes (ABgene, UK) in a T3 thermocycler 48 (Biometra,
Germany). Ten μl of amplified products were electrophoresed in 1 to 2% agarose gel at 135 V
for 30 min and afterwards stained with ethidium bromide for visualization under UV light. For
direct sequencing, PCR was performed in 50–100 μl volumes and amplicons were cleaned up
and concentrated using a PCR cleanup kit (QIAquick PCR Purification Kit, Qiagen, Germany)
Table 1. List of Ethiopian T. evansi isolates with data on origin and results in RoTat 1.2 PCR and EVAB PCR performed on DNA extracted from the
buffy coat specimens from the infected camels. pos: positive, neg: negative.
Stabilate code Region District Station RoTat 1.2 PCR EVAB PCR In vivo subpassages
before first cryostabilate
In vivo expansion
at ITM
MCAM/ET/2013/MU/01 Afar Megalle Adahara pos neg 3 yes
MCAM/ET/2013/MU/02 Tigray Raya-Azebo Chercher pos neg 5 yes
MCAM/ET/2013/MU/03 Tigray Raya-Azebo Kukufto pos neg 5 no
MCAM/ET/2013/MU/04 Tigray Raya-Azebo Chercher pos neg 3 yes
MCAM/ET/2013/MU/05 Tigray Raya-Azebo Balla pos neg 4 yes
MCAM/ET/2013/MU/06 Tigray Raya-Azebo Balla pos neg 3 yes
MCAM/ET/2013/MU/07 Afar Yallo Gubidera pos neg 2 yes
MCAM/ET/2013/MU/08 Afar Golina Ullel-ella pos neg 2 yes
MCAM/ET/2013/MU/09 Tigray Raya-Azebo Kukufto pos neg 3 yes
MCAM/ET/2013/MU/10 Afar Awash Fentale Alibete neg pos 2 yes
MCAM/ET/2013/MU/11 Afar Megalle Adahara pos neg 3 yes
MCAM/ET/2013/MU/12 Afar Yallo Gubidera pos neg 3 no
MCAM/ET/2013/MU/13 Afar Golina Ullel-ella pos neg 3 yes
MCAM/ET/2013/MU/14 Afar Awash Fentale Alibete neg pos 3 yes
MCAM/ET/2013/MU/15 Afar Awash Fentale Dihoon pos neg 2 yes
MCAM/ET/2013/MU/16 Afar Golina Ullel-ella pos neg 2 no
MCAM/ET/2013/MU/17 Afar Awash Fentale Dihoon pos neg 2 yes
MCAM/ET/2013/MU/18 Afar Megalle Adahara pos neg 2 no
MCAM/ET/2013/MU/19 Afar Megalle Adahara pos neg 3 no
MCAM/ET/2013/MU/20 Afar Golina Ullel-ella pos neg 2 no
MCAM/ET/2013/MU/21 Afar Megalle Adahara pos neg 3 no
MCAM/ET/2013/MU/22 Afar Megalle Adahara pos neg 3 no
doi:10.1371/journal.pntd.0004556.t001
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Table 2. PCRs used in the present study with target sequence, primer name and sequences, length of expected amplicon, reaction mixtures and
cycling conditions. Reaction mixture 1: 25 μl containing 25 ng DNA, 1X CoralLoad buffer, 1.5 mM of MgCl2, 200 μM of dNTPs, 0.5 μM of each primer, 0.5 U
of HotStar TaqPlus. Reaction mixture 2: 25 μl containing 25 ng DNA, 1X CoralLoad buffer, 1.5 mM of MgCl2, 200 μM of dNTPs, 1 μM of each primer, 0.5 U of
HotStar TaqPlus. Reaction mixture 3: 25 μl containing 25 ng DNA, 1X CloneAmp HiFi PCR premix and 0.25 μM of each primer. bp: base pair, P: Plus DNA
strand, M = Minus DNA strand.
Target
sequence
Primers Primer sequences Amplicon
length
Reaction
mixture
Cycling conditions Adapted
from
VSG RoTat
1.2
ILO7957 50-GCC ACC ACG GCG AAA GAC-30 488 bp 1 95°C for 5 min and 35
cycles of 30 sec at 94°C,
30 sec at 58°C, 30 sec at
72°C and final extension
for 5 min at 72°C
[43]
ILO8091 50-TAA TCA GTG TGG TGT GC-30 [43]
VSG JN
2118Hu
Forward 50-TTCTACCAACTGACGGAGCG-30 273 bp 1 95°C for 5 min and 35
cycles of 30 sec at 94°C,
30 sec at 55°C, 30 sec at
72°C and final extension
for 5 min at 72°C
[19]
Reverse 50-TAGCTCCGGATGCATCGGT-30 [19]
Maxicircle A6 Forward 50-AAAAATAAGTATTTTGATATTATTAAAG-30 381 bp 2 95°C for 5 min and 30
cycles of 94°C for 1 min,
54°C for 1 min, and 72°C
for 30 s followed by a
final elongation step at
72°C for 8 min
[44]
Reverse 50-TATTATTAACTTATTTGATC-30 [44]
Maxicircle
ND4
Forward 50-TGTGTGACTACCAGAGAT-30 256 bp 2 Idem as above [44]
Reverse 50-ATCCTATACCCGTGTGTA-30 [44]
Maxicircle
ND5
Forward 50-TGGGTTTATATCAGGTTCATTTATG-3 400 bp 2 Idem as above [28]
Reverse 50-CCCTAATAATCTCATCCGCAGTACG-30 [28]
Maxicircle
ND7
Forward 50-ATGACTACATGATAAGTA-3 167 bp 2 Idem as above [44]
Reverse 50-CGGAAGACATTGTTCTACAC-30 [44]
Minicircle
class A
MiniA 50-GGGTTTTTTAGGTCCGAG-30 1000 bp 1 95°C for 5 min and 35
cycles of 30 sec at 94°C,
30 sec at 58°C, 30 sec at
72°C and final extension
for 5 min at 72°C
[15]
Reverse
MiniB
50-CCGAAAATAGCACGTG-3’ [15]
Minicircle
class B
EVAB1 5’-CACAGTCCGAGAGATAGAG-3’ 436 bp 1 95°C for 5 min and 30
cycles of 30 sec at 94°C,
30 sec at 60°C, 60 sec at
72°C and final extension
for 10 min at 72°C
[15]
EVAB2 5’-CTGTACTCTACATCTACCTC-3’ [15]
Minisatellite
MORF2-REP
P 5’TGCATGGCAATAGCGATGGGC-3’ repeated
102 bp
sequence
1 95°C for 5 min and 30
cycles of denaturing at
94°C for 30 s, annealing
at 60°C for 30 sec and
extension at 72°C for 3
min. Elongation was
continued for 72°C for 5
min
[4]
M 5’ATCGTCACCTGGTGTACTTCTC-3’ [4]
(Continued)
Trypanosoma evansi Type B in Ethiopia
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004556 April 1, 2016 6 / 22
and sent out for bidirectional direct sequencing at the Genetic Sequencing Facility (VIB, Bel-
gium) using the described PCR primers.
The full length sequence of the F1-ATP synthase γ subunit was cloned into a BamHI and
HindIII double digested pHD309 vector using the In-Fusion Cloning kit (Clontech, Japan).
Primers contained a F1-ATP synthase γ subunit specific sequence based on the T. evansi
sequence of STIB 810 (EU185797) and a 50 extension of 15 bp specific to the place of integra-
tion in pHD309, containing the restriction sites and sequence overlap with the vector, as
required for the In-Fusion Cloning reaction. Proofreading-PCR was performed using the
Clone-Amp HiFi PCR premix (Clontech, Japan). Amplicons were cleaned up (QIAquick PCR
Purification Kit, Qiagen, Germany) before use in the In-Fusion protocol. The reaction products
were transformed in Stellar competent cells according to the manufacturer's recommendations
(Clontech, Japan). Transformant clones were checked for the presence of insert using colony
PCR, cultured in LB medium, plasmid purified (QIAprep Spin Miniprep Kit, Qiagen, Ger-
many) and at least 7 to 12 clones per transformation were bidirectionally sequenced at the
Genetic Sequencing Facility (VIB, Belgium) using primers binding to pHD309.
In vitro drug sensitivity testing
Melarsomine dihydrochloride (Cymelarsan, Sanofi Aventis, France) and isometamidium
hydrochloride (Veridium, Ceva Santé Animale, Belgium) were prepared as 10 mg ml−1 stock
solutions in distilled water. Dophanil powder (Dophanil, Docpharma, Belgium), containing
445 mg diminazene diaceturate and 555 mg antipyrine per gram, was concentrated to a 10 mg
ml−1 diminazene diaceturate solution in DMSO (Sigma, Belgium). Suramin (Germanin, Bayer,
Germany) was prepared as a 100 mg ml−1 in DMSO. A method to measure the IC50 values of
compounds in 96-well plates was performed as described elsewhere [46]. Briefly, 2 × 104 cells
ml−1 from in vitro adapted stocks were exposed to seven threefold drug dilutions, ranging from
5000 to 7 ng ml−1 for suramin, 500 to 0.7 ng ml−1 for diminazene diaceturate and from 250 to
0.35 ng ml−1 for melarsomine dihydrochloride and isometamidium hydrochloride, in a total
volume of 200 μl of HMI-9 medium. Next, the plate was incubated for 72 hours at 37°C with
5% CO2 followed by addition of 20 μl of resazurin (Sigma, Belgium; 12.5 mg in 100 ml PBS) for
measuring trypanosomes viability. After a further 24 h incubation at 37°C and 5% CO2,
Table 2. (Continued)
Target
sequence
Primers Primer sequences Amplicon
length
Reaction
mixture
Cycling conditions Adapted
from
TeAT1 TbAT1-F 5’-GAAATCCCCGTCTTTTCTCAC-3’ 1600 bp 1 95°C for 5 min, 24 cycles
of 1 min at 95°C followed
by 1 min at 56°C and 2
min at 72°C, and final
extension at 72°C for 5
min
[45]
TbAT1-R- 5’-ATGTGCTGAGCCTTTTTCCTT-3’ [45]
F1-ATP
synthase γ
subunit
F1-ATP-F 5’-AACTGCAACGAAGCTTATGTCGGGCAAGCTTCGTC-3’ 918 bp 3 98°C for 30 sand 35
cycles of 98°C for 15 s,
59.4°C for 15 s, 72°C for
20 s and 72°C for 5 min
followed by cool down to
4°C
F1-ATP-R 5’-
TAAATGGGCAGGATCCCTACTTGGTTACTGCCCCTTC-3’
doi:10.1371/journal.pntd.0004556.t002
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fluorescence was measured (excitation λ = 560 nm; emission λ = 590 nm) with a VictorX3 mul-
timodal plate reader using top reading (Perkin Elmer, Belgium) [42]. The results were
expressed as the percent reduction in parasite viability compared to the parasite viability in
control wells without drugs. The 50% inhibitory concentration (IC50) was calculated using
non-linear regression fitted with a (log) inhibitor versus normalised response (variable slope)
equation (GraphPad, version 6, USA). The IC50 values obtained from day 30 and day 60 in
vitro cultures were compared using t-tests corrected for multiple testing according to the
Holm-Sidak method (α = 0.05) (GraphPad, version 6, USA).
Microscopic examination for presence of a kinetoplast in trypanosomes
Trypanosome populations at different stages of in vivo and in vitro expansion were examined
for the presence of the kinetoplast using 4',6-diamidino-2-phenylindole (DAPI) staining.
Briefly, live trypanosomes in PSG or in vitro culture medium were washed in PBS by centrifu-
gation, deposited onto microscope slides, air dried and fixed with methanol for 30 min. Subse-
quently, the slides were rehydrated in PBS and mounted in 87% glycerol containing 1 μg ml-1
DAPI (Sigma, Belgium) [28]. Images were captured with an epifluorescence microscope
(Olympus BX41, Olympus, Japan) equipped with a NU fluorescent cube (excitation: 360–370
nm and emission> 420 nm)) and Cell^D software (Olympus, Japan). DAPI stained trypano-
somes were grouped according to the number of kinetoplasts (K) and nuclei (N) present within
each cell. The percentage of kinetoplastic cells in a DAPI stained slide was calculated on the
basis of on average 300 examined trypanosomes, by dividing the sum of 1K1N + 2K1N +
2K2N cells by the sum of 1K1N + 2K1N + 2K2N + 0K1N + 0K2N cells. A two-tailed Spearman
correlation matrix (using a confidence interval of 95%) was used to find the correlation
between the percentage of kinetoplastic cells at day 30 and day 60 of in vitro culture and the
respective IC50 value for a particular drug (GraphPad, version 6, USA).
In vivo infectivity check
To check the in vivo infectivity of trypanosome populations that were cryostabilised after con-
tinuous propagation in vitro for 60 days, 5 x 106 cells in 300 μl were inoculated in a single OF-1
mouse where after parasitaemia was checked as described above.
Results
Isolation of Ethiopian T. evansi stocks
Thirty cryopreserved buffy coat specimens from parasitologically positive dromedary camels
were inoculated in immunosuppressed Swiss albino mice. In total, 22 parasite stocks originat-
ing from 22 different animals could be isolated and cryopreserved after 2 to 5 subpassages in
mice. They were labelled as MCAM/ET/2013/MU/01 to MCAM/ET/2013/MU/22. Based on
positivity in RoTat 1.2 PCR and EVAB PCR of the corresponding cryopreserved buffy coats,
20 of these stocks are T. evansi type A and 2 are T. evansi type B (Table 1) [20]. Copy cryovials
of these primary isolates were brought to ITM, Antwerp and 14 were selected for further
expansion in mice. The selection was based on their geographical origin and subtype: 12 type A
stocks originated from different sampling stations in Afar and Tigray (MCAM/ET/2013/MU/
01, 02, 04, 05, 06, 07, 08, 09, 11, 13, 15, 17) and two type B stocks (MCAM/ET/2013/MU/10
and 14) were from Awash Fentale in Afar. At peak parasitaemia, between 4 to 7 DPI, parasites
were harvested, purified from blood using a mAECT column, washed with PSG and pelleted
for DNA extraction and for in vitro culture adaptation.
Trypanosoma evansi Type B in Ethiopia
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Molecular typing based on specific VSG sequences of in vivo expanded
stocks
DNA extracts of in vivo expanded stocks were subjected to RoTat 1.2 PCR and JN 2118Hu
PCR to identify the T. evansi type based on type-specific VSG sequences. In addition, the speci-
ficity of these PCRs was tested on DNA of other Trypanozoon strains (T.b. brucei AnTat 1.1E,
T.b. gambiense LiTat 1.3, T.b. gambiense type II ABBA, T. evansi type A RoTat 1.2, T. evansi
type B KETRI 2479 and T. equiperdum Dodola 940). Results are represented in Table 3. All the
in vivo expanded stocks that originated from RoTat 1.2 PCR positive buffy coats, were also pos-
itive in RoTat 1.2 PCR (MCAM/ET/2013/MU/01, 02, 04, 05, 06, 07, 08, 09, 11, 13, 15 and 17).
Table 3. Genetic characteristics of the trypanosome populations studied. pos = positive, neg = negative, seq = sequence identity, n.a. = not applicable,
n.d. = not done, (f) = faint, * amplification failed may be due to restricted elongation time in PCR protocol or probably high number of repeats present.
RoTat 1.2 JN 2118Hu Maxicircle PCR Minicircle
class
Fraction of kinetoplastic
cells in vivo
Minisatellite
profile
Trypanosome stock
or strain
PCR seq PCR seq ND4 ND5 ND7 A6 A B % MORF2-REP
T.b. brucei AnTat 1.1E neg n.a. pos identical pos pos pos pos pos
(f)
neg n.d. neg*.
T.b. gambiense LiTat
1.3
neg n.a. neg n.a. pos pos pos pos neg neg n.d. 7,11 (f)
T. b. gambiense ABBA neg n.a. pos G300A pos pos pos pos neg neg n.d. 3
T. evansi RoTat 1.2 pos identical neg n.a. neg neg neg neg pos neg 97 4,6
T. evansi KETRI 2479 neg n.a. pos identical neg neg neg neg neg pos 98 3,5
T. equiperdum Dodola
940
neg n.a. neg n.a. pos pos pos pos neg neg n.d. 11(f)
MCAM/ET/2013/MU/
001
pos identical neg n.a. neg neg neg neg pos neg 97 7
MCAM/ET/2013/MU/
002
pos identical neg n.a. neg neg neg neg pos neg 98 6,7
MCAM/ET/2013/MU/
004
pos C699A neg n.a. neg neg neg neg pos neg 99 6,7
MCAM/ET/2013/MU/
005
pos identical neg n.a. neg neg neg neg pos neg 98 6,7
MCAM/ET/2013/MU/
006
pos identical neg n.a. neg neg neg neg pos neg 99 6,7
MCAM/ET/2013/MU/
007
pos identical neg n.a. neg neg neg neg pos neg 100 6,7
MCAM/ET/2013/MU/
008
pos identical neg n.a. neg neg neg neg pos neg 98 6,7
MCAM/ET/2013/MU/
009
pos identical neg n.a. neg neg neg neg neg neg 0% 6,7
MCAM/ET/2013/MU/
010
neg n.a. pos identical neg neg neg neg neg pos 98 3,4
MCAM/ET/2013/MU/
011
pos identical neg n.a. neg neg neg neg pos pos
(f)
98 7
MCAM/ET/2013/MU/
013
pos identical neg n.a. neg neg neg neg pos neg 99 6,7
MCAM/ET/2013/MU/
014
neg n.a. pos identical neg neg neg neg neg pos 99 3,4
MCAM/ET/2013/MU/
015
pos n.d. pos n.d. neg neg neg neg pos pos 98 3,4,6,7
MCAM/ET/2013/MU/
017
pos identical neg n.a. neg neg neg neg pos pos
(f)
99 6,7
doi:10.1371/journal.pntd.0004556.t003
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Direct sequencing of the 488 bp amplicons from these putative T. evansi type A stocks and the
T. evansi RoTat 1.2 strain revealed 100% identity (in a 350 bp sequenced fragment) with the
published RoTat 1.2 VSG sequence (AF317914), thus identifying them as T. evansi type A.
Only one synonymous polymorphism (C699A) was found in MCAM/2013/ET/MU/04. The
gel with the RoTat 1.2 PCR products from the purified trypanosomes showed a faint band of
about 400 bp amplified in T. evansi KETRI 2479 and in MCAM/ET/2013/MU/10 and 14.
Direct sequencing of these 400 bp amplicons failed. The PCR targeting the T. evansi type B spe-
cific VSG JN 2118Hu generated the expected amplicon in T. evansi type B KETRI 2479 and in
MCAM/ET/2013/MU/10 and 14. Additionally, an amplicon was generated from MCAM/ET/
2013/MU/15. Also for T.b. brucei AnTat 1.1E and T.b. gambiense type II ABBA, amplicons of
273 bp were produced in the JN 2118Hu PCR. Direct sequencing of these amplicons revealed
that the Ethiopian T. evansi type B MCAM/ET/2013/MU/10 and 14, T. evansi type B KETRI
2479 and T.b. brucei AnTat 1.1E were 100% identical (in a 190 bp sequenced fragment) to the
corresponding sequence of JN 2118Hu VSG (AJ870486). In T.b. gambiense type II ABBA, one
synonymous mutation (G300A) was found.
Morphological and genotypic kDNA status of the in vivo expanded
stocks
Four PCRs that target maxicircle DNAs, of which three NADH-dehydrogenase subunits (ND4,
ND5, ND7) and the ATPase subunit 6 (A6), and two PCRs that target class-specific minicircle
sequences (miniA PCR and EVAB PCR) were run on DNA extracts of the purified trypano-
somes (Table 3). All Ethiopian T. evansi stocks and T. evansi type A RoTat 1.2 and T. evansi
type B KETRI 2479 were negative for all four maxicircle genes, while T.b. brucei AnTat 1.1E, T.
b. gambiense LiTat 1.3, T.b. gambiense type II ABBA and T. equiperdum Dodola 940 were posi-
tive for all four maxicircle genes.
All stocks that contain RoTat 1.2 VSG, except MCAM/ET/2013/MU/09, were positive in
miniA PCR. Additionally, weak amplification was seen in T.b. brucei AnTat 1.1E. MCAM/ET/
2013/MU/10 and 14 were positive in EVAB PCR, confirming their identification as T. evansi
type B as observed on their corresponding buffy coat specimens (Table 1). Additionally, EVAB
PCR amplicons were detected in 3 stocks that were also positive for RoTat 1.2 VSG PCR sug-
gesting a mixed infection with type A and B: a strong amplification was present in MCAM/ET/
2013/MU/15, while a weak amplification was visible in MCAM/ET/2013/MU/11 and 17. The
presence of kinetoplasts in the trypanosome cells was demonstrated using fluorescence micros-
copy with DAPI staining on ex vivo isolated trypanosomes (Table 3). T. evansi RoTat 1.2, T.
evansi KETRI 2479 and all but one Ethiopian T. evansi stocks show a kinetoplast in> 96% of
the cells. Stock MCAM/ET/2013/MU/09 was found to be akinetoplastic since only the nucleus
of the trypanosomes was visible with DAPI.
MORF2-REPminisatellite profile of the in vivo expanded stocks
In T. evansi RoTat 1.2, the MORF2-REP locus consists of 4 and 6 repeats, while in T. evansi
KETRI 2479, 3 and 5 repeats were found (Table 3). In vivo expanded Ethiopian stocks of type
A had either 1 allele (7 repeats) or 2 alleles (6 and 7 repeats), thus displaying a different pattern
than T. evansi type A RoTat 1.2. The Ethiopian type B stocks MCAM/ET/2013/MU/10 and 14
contain 3 and 4 repeats, and thus have a pattern different from T. evansi type B KETRI 2479.
MCAM/ET/2013/MU/15 showed a clear pattern of the Ethiopian type B (3 and 4 repeats), and
double allele pattern of the Ethiopian type A (6 and 7 repeats). The other presumed mixed type
A and type B stocks MCAM/ET/2013/MU/11 and 17 showed only the Ethiopian type A T.
evansi pattern (Fig 1). DNA extracted from the buffy coats revealed similar MORF2-REP
Trypanosoma evansi Type B in Ethiopia
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patterns as the in vivo expanded trypanosomes except for the buffy coat of MCAM/ET/2013/
MU/15 that revealed only the Ethiopian type A MORF2-REP pattern. The other Trypanozoon
strains showed the following patterns: T. b. gambiense LiTat 1.3 had 7 and 11 repeats, T.b. gam-
biense type II ABBA had 3 repeats, T. equiperdumDodola 940 had 11 repeats, while no ampli-
cons were generated from T.b. brucei AnTat 1.1E under the giving PCR conditions.
F1-ATP synthase γ subunit genotyping
Sequence analysis of in total 136 clones of the full length F1-ATP synthase γ subunit, amplified
from DNA of the in vivo expanded Ethiopian stocks MCAM/ET/2013/MU/04, 06, 09, 10, 11,
13, 14, 15 and of T.b. brucei AnTat 1.1E, T.b. gambiense LiTat 1.3, T. evansi RoTat 1.2, T. evansi
KETRI 2479, T. b. gambiense type II ABBA and T. equiperdum Dodola 940 revealed diverse
homozygous and heterozygous nucleotide polymorphisms spread over the entire coding
sequence (Table 4).
The F1-ATP synthase γ subunit of T.b. gambiense LiTat 1.3 (KT934830) appeared homozy-
gous and identical to the T.b. gambiense DAL972 sequence (Tbg972.10.90). T.b. gambiense
type II ABBA (KT934831) appeared homozygous and differed in only 2 SNPs (G801T and
A882G) from the T.b. gambiense sequence. T. evansi RoTat 1.2 and the Ethiopian stocks
MCAM/ET/2013/MU/04, 06, 09,11 and 13 were heterozygous and revealed in one allele
(KT934833), identical to the published full length T. evansi STIB 810 (EU185798) sequence,
the deletion of nucleotides A841-843del. The second allele contained a C142T polymorphism
(KT934832), that is not present in the wild-type T. evansi STIB 810 sequence (EU185797), but
that could be identified in the genome sequence of the Chinese akinetoplastic T. evansi STIB
805 strain [9]. For T. evansi KETRI 2479 and the Ethiopian stocks MCAM/ET/2013/MU/10
and 14 we obtained heterozygous alleles, different from the partial sequence of T. evansi
KETRI 2479 (EU185794). The first allele had the unique A844T polymorphism (KT934835),
and differed from the second allele in 3 additional SNPs (T321C, T807C, T867G) that were
also found in some T.b. brucei and T. equiperdum. Interestingly, the in vivo expanded stock of
MCAM/ET/2013/MU/15 revealed alleles that belonged to T. evansi type A and type B. In con-
trast, when the original buffy coat of this stock was tested, only alleles of T. evansi type A were
found. Finally, T. equiperdum Dodola 940 (KT934836) appeared homozygous and its single
Fig 1. MORF2-REP profiles of Ethiopian T. evansi stocks and T. evansi and T. brucei reference strains. 1.5% agarose gel showing MORF2-REP
minisatellite PCR amplicons. Lane M: 100 bp plus marker, lanes 1 to 14: Ethiopian T. evansi stocks MCAM/ET/2013/MU/01-02-04-05-06-07-08-09-10-11-13-
14-15-17, lane 15: T.b. gambiense LiTat 1.3, lane 16: T.b. brucei AnTat 1.1E lane 17: T. evansi type A (RoTat 1.2), lane 18: T. evansi type B (KETRI 2479),
lane 19: T. equiperdum Dodola 940, lane 20: T. b. gambiense ABBA, lane N: negative control
doi:10.1371/journal.pntd.0004556.g001
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allele was identical to one of the two alleles found in T.b. brucei AnTat 1.1E (KT934837), but
differed in 5 SNPs with the sequence from T. equiperdum BoTat 1.1 (EU185793) and in 6 SNPs
with T. equiperdum STIB 841 (EU185792). However, for the T. equiperdum STIB 841 strain, 5
of the 6 SNPs were ambiguous polymorphisms that do not rule out similarity to T. equiperdum
Dodola 940.
In vitro adaptation of Ethiopian T. evansi stocks
Fourteen Ethiopian T. evansi stocks, T. evansi RoTat 1.2 and T. evansi KETRI 2479 were
expanded in mice and purified from blood at peak parasitaemia to initiate primary in vitro cul-
tures in HMI-9 (HS) medium. After 96 hours, the initial 2x104 cells ml−1 inoculum reached
concentrations above 2x105 cells ml−1 for all the different stocks. These cells were used for fur-
ther in vitro propagation by subpassage in fresh medium. Over the next 72 hours, only
MCAM/ET/2013/MU/09, 14 and 15, and T. evansi RoTat 1.2 and T. evansi KETRI 2479
showed proliferation. In contrast, slightly increased cell densities were observed for MCAM/
ET/2013/MU/01, 04, 06 and 10. For all other strains not a single inoculum proliferated and
longer incubation led to growth cessation.
Because the HMI-9 (HS) medium did not support sufficient in vitro culture growth for
most of the Ethiopian T. evansi stocks, it was abandoned and replaced with HMI-9 without
horse serum. In vitro adapted strains of T.b. brucei AnTat 1.1E and T.b. gambiense LiTat 1.3
were cultured in HMI-9 in parallel. In vitro cultures were only considered adapted to HMI-9
medium when it was possible to maintain the parasites in continuous proliferation. To this
extent, dense parasite cultures, containing 2–5 x 105 cells ml−1, were subpassaged into new
wells using serial fivefold dilutions in fresh medium. When these subpassages reached densities
above 2 x 105 cells ml−1 within a 48–96 hours period, the stock was considered adapted. The
five stocks that already grew well in the HMI-9 (HS) medium continued proliferating when
inoculated from the dense cultures at serial fivefold dilutions in HMI-9. These five stocks were
considered to be in vitro adapted after 15 days of in vitro culture. Out of the four remaining
stocks, only MCAM/ET/2013/MU/04 and 10 slowly regained the ability to proliferate in HMI-
9 at a reduced subpassaging scheme using serial twofold dilutions. MCAM/ET/2013/MU/04
required 25 days to adapt, while MCAM/ET/2013/MU/10 was only fully adapted after day 35
of in vitro culture. Gradually increasing the culture volume allowed to obtain sufficient para-
sites from the adapted cultures for in vitro drug testing, DNA extraction, and cryostabilisation
at day 30 (all, except MCAM/ET/2013/MU/10) and at day 60 of in vitro culture (all stocks).
DNA of the in vitro adapted stocks was subjected to RoTat 1.2 PCR, EVAB PCR and MOR-
F2-REP PCR. All in vitro stocks had similar molecular profiles as their corresponding in vivo
expanded parental stocks, except MCAM/ET/2013/MU/15. While the in vivo expanded stock
of the latter was identified as a mixed infection of T. evansi type A and type B, the in vitro
adapted stock (at day 30 and day 60 in vitro culture) was identified as pure T. evansi type B
with the above mentioned PCRs and confirmed by cloning and sequencing of the F1-ATP
synthase γ subunit. Thus, beside T. evansi RoTat 1.2 and T. evansi KETRI 2479, we achieved
the in vitro adaptation of 2 Ethiopian type A stocks, 2 Ethiopian type B stocks and additionally
ended up with a pure T. evansi type B in vitro adapted stock originating from a mixed type A
and type B in vivo adapted stock. Growth curves were generated for T.b. brucei AnTat 1.1E and
all seven in vitro adapted stocks (Fig 2). T.b. brucei AnTat 1.1E and T. evansi RoTat 1.2 had the
shortest Td, 7.5 ± 0.3 h
-1 and 7.7 ± 0.2 h-1 respectively, and reached the highest maximum pop-
ulation density (MPD) of ± 3–4 x 106 cells ml-1, while T. evansi KETRI 2479 had a longer Td,
10.8 ± 0.2 h-1, and a lower MPD of ± 1 x 106 cells ml-1. The Ethiopian type A stocks MCAM/
ET/2013/MU04 and MU09 had a Td of 11.2 ± 0.4 and 11.3 ± 0.4 respectively, and a MPD
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of ± 1 x 106 cells ml-1. Similarly, the Ethiopian type B stocks MCAM/ET/2013/MU10, 14 and
15 had a Td of 12.9 ± 0.5, 11.3 0.5 and 12.1 ± 0.6 respectively, and a MPD of ± 0.7–1 x 10
6 cells
ml-1 (Fig 2).
In vitro drug sensitivity and relation to kDNA
After day 30 and 60 of in vitro culture, IC50 values were determined for melarsomine dihy-
drochloride (Cymelarsan) (Fig 3A), isometamidium hydrochloride (Veridium) (Fig 3B),
diminazene diaceturate (Dophanil) (Fig 3C) and suramin (Germanin) (Fig 3D). In general,
non-significant differences (p> 0.05) were found between IC50 values recorded at day 30 and
day 60 of in vitro culture, except for the melarsomine dihydrochloride IC50 values of T. evansi
RoTat 1.2 and T. evansiMCAM/ET/2013/MU/14 and for the isometamidium hydrochloride
IC50 values of T. evansi KETRI 2479 and T. evansiMCAM/ET/2013/MU/09 (p< 0.05). For
comparison between the different stocks, the IC50 values of day 30 and day 60 of in vitro cul-
tures were averaged. All Ethiopian T. evansi stocks had IC50 values for melarsomine dihy-
drochloride (IC50 1.9–3.3 ng ml
-1) that were similar to those of T.b. gambiense LiTat 1.3 (IC50
4.3 ng ml-1), T.b. brucei AnTat 1.1E (IC50 6.8 ng ml
-1), T. evansi RoTat 1.2 (IC50 3.0 ng ml
-1)
and T. evansi KETRI 2479 (IC50 4.1 ng ml
-1). For isometamidium hydrochloride, the IC50 val-
ues of the Ethiopian T. evansi (IC50 0.6–6.2 ng ml
-1) fall within the range of T.b. gambiense
LiTat 1.3 (IC50 0.1 ng ml
-1), T.b. brucei AnTat 1.1E (IC50 7.3 ng ml
-1), T. evansi RoTat 1.2 (IC50
7.1 ng ml-1) and T. evansi KETRI 2479 (IC50 5.5 ng ml
-1). However, the two Ethiopian T. evansi
type A stocks (IC50 4.3–6.2 ng ml
-1) appear to be threefold less sensitive that the three type B
stocks (IC50 0.6–1.9 ng ml
-1). For suramin, large differences in IC50 values were found among
the Ethiopian T. evansi (IC50 15.9–261.5 ng ml
-1) stocks and among the other strains: T.b. bru-
cei AnTat 1.1E (IC50 39.5 ng ml
-1) and T. evansi RoTat 1.2 (IC50 35.8 ng ml
-1) appear highly
susceptible, while T.b. gambiense LiTat 1.3 (IC50 134.0 ng ml
-1) and T. evansi KETRI 2479
(IC50 222.4 ng ml
-1) are less susceptible. The two Ethiopian T. evansi type A (IC50 153.5–261.5
ng ml-1) appear to be tenfold less sensitive than the three type B (IC50 15.9–27.6 ng ml
-1). For
diminazene diaceturate, the IC50 values of all Ethiopian T. evansi (IC50 17.5–48.5 ng ml
-1) are
higher than those of T.b. gambiense LiTat 1.3 (IC50 5.2 ng ml
-1) and T. evansi RoTat 1.2 (IC50
13.8 ng ml-1), but similar to T.b. brucei AnTat 1.1E (IC50 39.6 ng ml
-1) and T. evansi KETRI
2479 (IC50 24.0 ng ml
-1). The two Ethiopian T. evansi type A (IC50 37.4–48.5 ng ml
-1) appear
to be twofold less sensitive than the three type B (IC50 17.5–25.9 ng ml
-1). Direct sequencing of
the full length TeAT1 PCR amplicons of MCAM/ET/2013/MU/04, 09, 10, 14, and 15, T. evansi
Fig 2. In vitro growth curve of trypanosome stocks and strains. T.b.b. = T.b. brucei, T.e. = T. evansi,
MU = MCAM/ET/2013/MU.
doi:10.1371/journal.pntd.0004556.g002
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type A RoTat 1.2 and T. evansi Type B KETRI 2479 revealed no polmorphisms to the wild-type
TeAT1 sequence (AB124588).
DAPI staining was performed on in vivo and in vitro propagated stocks (Fig 4). In vitro cul-
ture did not change the percentage of kinetoplastic cells in T.b. gambiense LiTat 1.3 (99%), T.b.
brucei AnTat 1.1E (99%) and MCAM/ET/2013/MU/09 (0%). On the other hand, already after
30 days in vitro culture a decrease in the percentage of kinetoplastic cells was observed in T.
evansi RoTat 1.2 (89%), T. evansi KETRI 2479 (81%), MCAM/ET/2013/MU/04 (97%), 14
(93%) and 15 (94%) compared to non-in vitro adapted trypanosomes. After 60 days of in vitro
Fig 3. In vitro drug sensitivity of T. evansi. IC50 values for different drugs, with standard deviation error bars, obtained with different Trypanosoma sp.
stocks and strains after 30 (black bars) and 60 days (grey bars) in vitro culture. Significant differences between IC50 values of 30 and 60 days in vitro cultures
are indicated by an asterisk. T.b.g. = T.b. gambiense, T.b.b. = T.b. brucei, T.e. = T. evansi, MU = MCAM/ET/2013/MU. Panel A: IC50 values for melarsomine
dihydrochloride. Panel B: IC50 values for isometamidium hydrochloride. Panel C. IC50 values for suramin and Panel D: IC50 values for diminazene
diaceturate.
doi:10.1371/journal.pntd.0004556.g003
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culture, the percentage of kinetoplastic cells dropped even further for T. evansi KETRI 2479
(64%), MCAM/ET/2013/MU/04 (89%) and 10 (35%). No significant correlation was observed
between the percentage of kinetoplastid cells of all in vitro adapted T. evansi stocks (including
day 30 and day 60) and their IC50 values for melarsomine dihydrochloride (ρ = -0.13, p = 0.
67), isometamidium hydrochloride (ρ = -0.324, p = 0.278), suramin (ρ = -0.097, p = 0.752) and
diminazene diacetureate (ρ = -0.355, p = 0.233). These data suggest that among the in vitro
adapted Ethiopian T. evansi stocks there is no relation between the drug sensitivity and the
presence of kinetoplast DNA. Furthermore, their loss of kDNA does not seem to influence
rodent infectivity since all cryostabilates made from day 60 in vitro cultures remained infective
for mice with detectable parasitaemia at 4–5 DPI.
Discussion
Previous molecular and serological studies revealed that trypanosome infections in camels
from Northern Ethiopia are caused by either RoTat 1.2 PCR or EVAB PCR positive parasites.
In some instances amplicons of both PCRs were detected within the same buffy coat extract,
suggesting the occurrence of mixed infections [20]. The present study was undertaken to isolate
the trypanosomes from camels carrying apparent single infections through inoculation of their
buffy coats in immunosuppressed mice. The in vivo inoculation led to the successful isolation
of 22 stocks, out of which 14 were selected on the basis of their geographical origins for further
investigations (5 stocks from Tigray and 9 stocks from Afar). Next, we performed an in-depth
comparative molecular analysis on DNA extracts from the isolated parasite stocks using diverse
PCRs. Furthermore, we analysed the specificity of each of these PCRs on a collection of Trypa-
nozoon strains.
The RoTat 1.2 VSG sequence can be used to characterise T. evansi type A [25,43]. In our col-
lection, all buffy coats positive in RoTat 1.2 PCR yielded in vivo isolated stocks that were RoTat
Fig 4. Percentage of kinetoplastic cells within T. evansi populations. Percentage of kinetoplastic cells
visualised after DAPI staining and fluorescence microscopy within populations after 30 (black bars) and 60
days (grey bars) in vitro propagation. T.b.g. = T.b. gambiense, T.b.b. = T.b. brucei, T.e = T. evansi,
MU = MCAM/ET/2013/MU.
doi:10.1371/journal.pntd.0004556.g004
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1.2 PCR positive but that were negative in the maxicircle gene targeting PCRs. Furthermore, with
the exception of the akinetoplastic stock MCAM/ET/2013/MU/09, all these strains had type A
minicircles. MCAM/ET/2013/MU/09 may be naturally akinetoplastic since the DNA extracted
from the original buffy coat was negative in all PCRs targeting kinetoplast DNA. The occurrence
of naturally akinetoplastic strains was previously documented in Latin America and China [12–
14,47]. One stock (MCAM/ET/2013/MU/04) contained a SNP in its RoTat 1.2 VSG PCR ampli-
con. SNPs in RoTat 1.2 amplicons were previously reported in Egypt but do not necessarily lead
to a negative result in RoTat 1.2 based antibody detection tests. This was also the case for the
camel from which MCAM/ET/2013/MU/04 was isolated [48,49].
Initially defined by minicircle class B, identification of T. evansi type B is possible with
EVAB PCR that amplifies a fragment of this minicircle [15]. Additionally, it was proposed that
the VSG JN 2118Hu, first described in a Kenyan T. evansi strain, is a specific marker for T.
evansi type B [19].
In our collection, 2 buffy coat extracts that were positive in EVAB PCR yielded in vivo iso-
lated stocks that were EVAB PCR positive as well. Interestingly, an EVAB PCR amplicon was
also detected in three additional in vivo expanded stocks that were RoTat 1.2 PCR positive but
for which the corresponding buffy coats were EVAB PCR negative. These three stocks might
be mixed infections. JN 2118Hu VSG PCR appeared to be less sensitive because it detected
only 3 out of 5 EVAB PCR positive isolated stocks. Furthermore, the JN 2118Hu VSG PCR
appeared to be less specific since T.b. brucei AnTat 1.1E and T.b. gambiense type II ABBA were
also positive in this PCR. None of the EVAB PCR positive isolated stocks contained maxicircle
DNA and they were all negative in miniA PCR, except for the three mixed infections. There-
fore, we conclude that we isolated at least two “pure” T. evansi type B stocks from Ethiopian
camels, decades after the initial isolation of T. evansi type B from camels in Kenya [15].
We used the minisatellite locus MORF2-REP to verify whether both putative mixed stocks,
that were positive in RoTat 1.2 PCR and EVAB PCR, were real mixed infections or hybrids
between T. evansi type A and B. The Ethiopian isolates clustered in two classes of T. evansi
type A, of which one with a previously described heterozygous profile (6 and 7 repeats) and
one with a homozygous profile (7 repeats). The Ethiopian T. evansi type B stocks had a hetero-
zygous profile (3 and 4 repeats) differing from the only known profile described for Kenyan
type B isolates (3 and 5 repeats) [50]. In one of the mixed infections we observed a profile that
can be interpreted as a mixture of Ethiopian type A and type B, while the others only revealed
the Ethiopian type A pattern. These results prove that we are dealing with mixed infections and
not with hybrids between T. evansi type A and type B. To exclude that these apparent mixed
infections represent cross-contamination with genetic material, we attempted in vitro cultiva-
tion of the in vivo expanded stocks.
Previously we have shown that addition of 1,1% methylcellulose to HMI-9 greatly helps the
in vitro adaptation of Trypanozoon strains, including T.b. gambiense and T. evansi RoTat 1.2
[40]. However, to avoid the use of this highly viscous medium we preferred the use of horse
serum to adapt T. evansi stocks as is suggested in previous reports [51–53]. While this
approach proved to be successful for all type B stocks, only two out of nine Ethiopian T. evansi
type A could be adapted. Interestingly, in the case of mixed stock MCAM/ET/2013/MU/15,
this medium selected T. evansi type B out of the mixed population. While only the type A infec-
tion was detected in the buffy coat DNA extract, both types could be detected in the in vivo
expanded stock DNA, but eventually only type B was detected in the in vitro adapted stock.
Gillingwater and colleagues reported on the drug sensitivity profiles of a panel of T. evansi
and T. equiperdum strains where they considered T. evansi STIB 806K to be a reference sensi-
tive strain for suramin (IC50 70.4 ng ml
-1), diminazene diaceturate (IC50 4.5 ng ml
-1) and mel-
arsomine dihydrochloride (IC50 1.4 ng ml
-1). They reported drug resistance in two T. evansi
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stocks with an IC50 for suramin> 10000 ng ml
-1 (STIB 780 and STIB 781), and in the T. equi-
perdumOVI strain, with an IC50 for diminazene diaceturate of 302 ng ml
-1 and an IC50 for
melarsomine dihydrochloride of 17.6 ng ml-1 [46]. The only strain that is shared between their
panel and our collection is T. evansi RoTat 1.2, which despite different approaches in the exper-
imental testing, yielded corresponding IC50 values, especially for diminazene diaceturate and
melarsomine dihydrochloride, thus facilitating comparison between both studies. In our Ethio-
pian T. evansi collection, no resistance against melarsomine dihydrochloride was found. How-
ever, some stocks appeared to have raised IC50 values for suramin (> 200 ng ml
-1) and
diminazene diaceturate (> 50 ng ml-1). The IC50 values that we observe for T.b. gambiense
LiTat 1.3 and the Ethiopian T. evansi type B are similar to the in vitro IC50 value of 0.82 ng ml
-1
found by Sahin and coworkers for T. congolense IL3000 which is sensitive to isometamidium
(Veridium) in vivo [54]. In the same study, an in vitro IC50 of 11.06 ng ml
-1 is reported for T.b.
brucei AnTat 1.1 strain, which is slightly higher than the value that we obtained in experiments
with our T.b. brucei AnTat 1.1 strain and the other T. evansi stocks [54]. Nevertheless, defining
our T. evansi stocks as either sensitive or resistant based solely on the in vitro drug sensitivity
results may be too audacious, given the fact that IC50 values were determined in only one assay,
the resazurin viability assay [55–57]. Therefore, an in vivo drug sensitivity profile of all our Try-
panozoon strains against the commonly used trypanocides remains to be elucidated. Interest-
ingly, both Ethiopian T. evansi type A stocks appear to be less susceptible to suramin,
diminazene diaceturate and isometamidium hydrochloride than the three type B stocks. In T.b.
brucei, resistance against suramin and isometamidum hydrochloride has been linked to several
proteins [58,59], while resistance to diamidine and melaminophenyl classes of drugs is attrib-
uted to the transporter protein TbAT1 and the aquaporin AQP2 [60–62]. The lower sensitivity
to diminazene diaceturate was not caused by mutations in the T. evansi TeAT1 [63].
Interestingly, DAPI staining of the trypanosomes indicated slight to severe loss of the
kDNA in all in vitro adapted T. evansi stocks, when compared to in vivo adapted stocks. The
loss of kDNA in in vitro cultured T. evansi is a phenomenon that has been known for a long
time [10,15,55,64]. Non-vital loss of the kinetoplast is made possible by mutations in the
F1-ATP synthase γ subunit of T. evansi allowing to uncouple from the Fo subunit and effec-
tively circumventing the requirement for mitochondrial gene expression [65]. Furthermore, it
has been shown that the expression of certain T. evansi F1-ATP synthase γ subunit coding
sequences in T. brucei allows this species to survive loss of its kDNA after chemical treatment
[28]. Moreover, in such genetically modified T. brucei, independence of kDNAmaintenance
and expression is associated with multidrug resistance [30]. In our collection of T. evansi stocks
we did not observe differences in drug sensitivity between populations that were partially or
completely akinetoplast confirming earlier evidence that the presence or absence of kDNA is
irrelevant within this context [30,55].
Recently, Carnes et al. showed that SNPs in the F1- ATP γ subunit could be used to geno-
typically support the multiple origins of at least 4 dyskinetoplastic T. evansi/T. equiperdum lin-
eages: one major group of RoTat 1.2 VSG positive T. evansi/T. equiperdum type A, and three
very small groups each represented by only a single strain: T. evansi type B KETRI 2479, T.
equiperdum BoTat and T. equiperdum OVI [9]. All Ethiopian T. evansi type A had the corre-
sponding mutation of the type A group. The Ethiopian type B T. evansi shared a similar profile
as KETRI 2479. Finally, the Ethiopian T. equiperdum strain Dodola, which had some maxicir-
cle genes but was negative for both type A and type B markers revealed an F1-ATP synthase
sequence similar to T.b. brucei AnTat 1.1E strain, thus likely belongs to the same dyskinetoplas-
tic group as T. equiperdumOVI [9,28].
In conclusion, our study shows that the apparent T. evansi type that is detected in a buffy
coat of an infected camel does not necessarily represent the full diversity that is present in the
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infected animal. Moreover, the fact that 5 out of 22 new T. evansi isolates from camel in Ethio-
pia contain T. evansi type B may be an indication that is more widespread than currently
known. The inoculation of the trypanosomes in immunosuppressed mice may allow the propa-
gation of mixed populations. In contrast, in vitro cultivation seems to reduce the diversity by
selecting for only one particular type, in our study T. evansi type B. Secondly, our study
addresses some drawbacks of current molecular markers for T. evansi genotyping. To rely
solely on VSG markers or kDNA markers for the molecular identification of T. evansimay be
misleading due to possible recombinations occurring in VSG genes and to the presence of aki-
netoplastic T. evansi stocks. In this regard, we confirm that the F1-ATP synthase γ subunit
gene, that is not related to the VSG repertoire nor to the presence of kDNA, may become an
interesting target for genotyping T. evansi stocks in areas where both types overlap and where
mixed infections can occur. Nevertheless, it is not possible to separate the Ethiopian T. equiper-
dum from T. brucei on the basis of this target gene. Thirdly, no evidence of in vitro drug resis-
tance was found in our collection of T. evansi type A and type B stocks. The presence or partial
absence of kDNA in the in vitro adapted T. evansi stocks did not correspond with the drug sen-
sitivity phenotype.
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